Aerolase Revenue and Competitors

Tarrytown, NY USA

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • Aerolase's estimated annual revenue is currently $12.5M per year.(i)
  • Aerolase's estimated revenue per employee is $140,000

Employee Data

  • Aerolase has 89 Employees.(i)
  • Aerolase grew their employee count by 7% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$27.2M181-36%$162.2MN/A
#2
$3.8M3470%N/AN/A
#3
$3.6M32-18%N/AN/A
#4
$58.9M331-17%$26.9MN/A
#5
$4.7M4227%N/AN/A
#6
$197M1502-8%$112.6MN/A
#7
$22.6M150-8%$45MN/A
#8
$21.6M0N/A$13.2MN/A
#9
$4070M4236-21%$1.9BN/A
#10
$5.4M4823%N/AN/A
Add Company

Aerolase is a worldwide technology leader for laser skin health. Our lasers are the product of more than two decades of research and development. Aerolase provides integrated solutions to the most commonly seen dermatological conditions and in-demand aesthetic procedures. Our lasers substantially improve treatment outcomes and patient experiences, help physicians practice medicine profitably, and reduce the overall costs of care in an evolving healthcare market.

keywords:N/A

N/A

Total Funding

89

Number of Employees

$12.5M

Revenue (est)

7%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Aerolase News

2022-04-19 - Aesthetic Laser Market Size And Forecast | Aerolase Corp ...

Aerolase Corp., Lumenis Ltd., El. En SpA, Cynosure Cutera Alma Lasers, Sciton Sharplight Technologies Ltd., Solta Medical and Syneron...

2022-04-17 - Aerolase Expands into Canada with Significant Order Backlog ...

TARRYTOWN, N.Y. , April 13, 2022 /PRNewswire/ -- Continuing its global expansion, Aerolase is delighted to announce two positive recent...

2022-03-22 - Aerolase Further Extends Treatment Range for Its Universal ...

Aerolase® is a global technology leader in laser skin health and the only developer and manufacturer in the world of portable high-power lasers...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$16.9M94-2%N/A
#2
$13.2M94N/AN/A
#3
N/A10314%N/A
#4
$29.7M11020%N/A
#5
$15M11616%N/A